According to Zacks, “Aravive Inc. is a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. Aravive Inc. is based in TX, United States. “
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Wedbush set a $269.00 target price on shares of United Therapeutics and gave the stock a buy rating in a report on Monday, April 8th. Finally, Piper Jaffray Companies upped their target price on shares of Boot Barn from $33.00 to $41.00 and gave the stock an overweight rating in a report on Monday, May 13th.
ARAV opened at $5.90 on Wednesday. The company has a current ratio of 7.78, a quick ratio of 7.78 and a debt-to-equity ratio of 0.17. Aravive has a fifty-two week low of $3.07 and a fifty-two week high of $12.60. The stock has a 50-day simple moving average of $5.93.
Aravive (NASDAQ:ARAV) last posted its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.44. The business had revenue of $1.70 million during the quarter. Equities analysts forecast that Aravive will post -2.19 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of ARAV. BlackRock Inc. purchased a new stake in Aravive in the 4th quarter valued at about $621,000. Dimensional Fund Advisors LP purchased a new stake in Aravive in the 4th quarter valued at about $484,000. Two Sigma Investments LP purchased a new stake in Aravive in the 4th quarter valued at about $124,000. Geode Capital Management LLC purchased a new stake in Aravive in the 4th quarter valued at about $105,000. Finally, Two Sigma Advisers LP purchased a new stake in Aravive in the 4th quarter valued at about $87,000. Institutional investors own 27.57% of the company’s stock.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
See Also: What is a Swap?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.